TCR2(TCRR) Therapeutics Inc, initiated with $30.75 average Target.

March 12th, 2019

TCR² is a clinical-stage immunotherapy company developing a new generation of T cell therapies for patients suffering from cancer.

STA Research Full Report:STA-TCRR-2019-03-12

 

Leave a Reply

Your email address will not be published. Required fields are marked *